Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SLOG Regimen in Metastatic Pancreatic Adenocarcinoma
NCT01415713Phase 2Completed
- Sponsor
- National Health Research Institutes
- Start
- Mar 2012
- Primary completion
- Apr 2016
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of tegafur, folinic acid, oxaliplatin, gemcitabine in pancreatic adenocarcinoma (PDAC), sponsored by National Health Research Institutes. Started Mar 2012; status: completed.
02
Drugs
tegafurfolinic acidoxaliplatingemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT01415713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01415713.